BioCentury | Mar 6, 2020
Management Tracks

Sharp steps down as Ultragenyx CFO; plus Axsome, ElevateBio, FasterCures, Satsuma, WindMIL and more

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) said EVP and CFO Shalini Sharp will step down by Sept. 2 to focus on serving as an adviser and board member for various biotech companies. Sharp will remain with the...
BC Extra | Dec 24, 2019
Company News

Dec. 23 Company Quick Takes: Theravance partners with Pfizer; plus Fortress-AZ, Progenics, Tracon-Alphamab Oncology-3D Medicines

Theravance gains $10M upfront in Pfizer deal  Theravance Biopharma Inc. (NASDAQ:TBPH) granted Pfizer Inc. (NYSE: PFE) exclusive, worldwide rights to its skin-targeted, locally-acting pan-JAK inhibitor program for undisclosed skin conditions. Theravance will receive $10 million...
BC Extra | Nov 23, 2019
Company News

Management tracks: Sanofi head of strategy Mansuri set to retire; plus Arrakis, MorphoSys, Kymera, Kronos, Kite, Twist, Cerevel, Coda, Science 37, and more

Sanofi (Euronext:SAN; NASDAQ:SNY) said Muzammil Mansuri, EVP, head of strategy and business development, will retire at the end of the month. His responsibilities will be divided between Alban de La Sablière, head of business development,...
BC Extra | Nov 14, 2019
Company News

Management tracks: Longtime Abbott CEO resigning; plus Otsuka, Bavarian Nordic, Progenics and Rakuten

Miles White will step down as CEO of Abbott Laboratories (NYSE:ABT) on March 31, after 21 years in the role while remaining executive chairman. President and COO Robert Ford, who joined the company in 1996,...
BC Extra | Oct 2, 2019
Company News

Imaging company Lantheus enters therapeutics with Progenics takeout

Lantheus plans to acquire Progenics in an all-stock deal, creating a path for the medical imaging company to move into therapeutics. Based on the 86.4 million outstanding shares of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) and the...
BC Extra | Jun 22, 2019
Clinical News

June 21 Clinical Quick Takes: Melanoma miss for Exelixis/Genentech combo; plus Progenics, Turning Point, Gracell

Cotellic/Tecentriq combo misses in melanoma  Exelixis Inc. (NASDAQ:EXEL) revealed in a Thursday SEC filing that Cotellic cobimetinib plus Tecentriq atezolizumab from partner Genentech Inc. missed the primary endpoint of improving progression-free survival vs. Keytruda pembrolizumab...
BioCentury | Mar 1, 2019
Product Development

Prostate cancer disrupted

Two imminent disruptions threaten to upend the treatment landscape for prostate cancer, changing who gets anti-androgen therapies and ushering in the first new MOAs in decades. The launch of generic abiraterone means next generation anti-androgens...
BioCentury | Oct 6, 2018
Finance

Large cap comeback

The biotech sector continued to be a stock pickers’ market through 3Q18 as there was a near even split between global biotech stocks that gained and lost value in the quarter. While 1H18 saw investors...
BioCentury | Oct 6, 2018
Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
BC Week In Review | Sep 21, 2018
Clinical News

Progenics' prostate cancer imaging agent meets specificity endpoint in Phase III

Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) said SPECT/CT imaging with its 99mTc-MIP-1404 (1404, F-1311) imaging agent met the co-primary endpoint of specificity but missed the co-primary endpoint of sensitivity in a Phase III trial to detect low-grade...
Items per page:
1 - 10 of 565
BioCentury | Mar 6, 2020
Management Tracks

Sharp steps down as Ultragenyx CFO; plus Axsome, ElevateBio, FasterCures, Satsuma, WindMIL and more

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) said EVP and CFO Shalini Sharp will step down by Sept. 2 to focus on serving as an adviser and board member for various biotech companies. Sharp will remain with the...
BC Extra | Dec 24, 2019
Company News

Dec. 23 Company Quick Takes: Theravance partners with Pfizer; plus Fortress-AZ, Progenics, Tracon-Alphamab Oncology-3D Medicines

Theravance gains $10M upfront in Pfizer deal  Theravance Biopharma Inc. (NASDAQ:TBPH) granted Pfizer Inc. (NYSE: PFE) exclusive, worldwide rights to its skin-targeted, locally-acting pan-JAK inhibitor program for undisclosed skin conditions. Theravance will receive $10 million...
BC Extra | Nov 23, 2019
Company News

Management tracks: Sanofi head of strategy Mansuri set to retire; plus Arrakis, MorphoSys, Kymera, Kronos, Kite, Twist, Cerevel, Coda, Science 37, and more

Sanofi (Euronext:SAN; NASDAQ:SNY) said Muzammil Mansuri, EVP, head of strategy and business development, will retire at the end of the month. His responsibilities will be divided between Alban de La Sablière, head of business development,...
BC Extra | Nov 14, 2019
Company News

Management tracks: Longtime Abbott CEO resigning; plus Otsuka, Bavarian Nordic, Progenics and Rakuten

Miles White will step down as CEO of Abbott Laboratories (NYSE:ABT) on March 31, after 21 years in the role while remaining executive chairman. President and COO Robert Ford, who joined the company in 1996,...
BC Extra | Oct 2, 2019
Company News

Imaging company Lantheus enters therapeutics with Progenics takeout

Lantheus plans to acquire Progenics in an all-stock deal, creating a path for the medical imaging company to move into therapeutics. Based on the 86.4 million outstanding shares of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) and the...
BC Extra | Jun 22, 2019
Clinical News

June 21 Clinical Quick Takes: Melanoma miss for Exelixis/Genentech combo; plus Progenics, Turning Point, Gracell

Cotellic/Tecentriq combo misses in melanoma  Exelixis Inc. (NASDAQ:EXEL) revealed in a Thursday SEC filing that Cotellic cobimetinib plus Tecentriq atezolizumab from partner Genentech Inc. missed the primary endpoint of improving progression-free survival vs. Keytruda pembrolizumab...
BioCentury | Mar 1, 2019
Product Development

Prostate cancer disrupted

Two imminent disruptions threaten to upend the treatment landscape for prostate cancer, changing who gets anti-androgen therapies and ushering in the first new MOAs in decades. The launch of generic abiraterone means next generation anti-androgens...
BioCentury | Oct 6, 2018
Finance

Large cap comeback

The biotech sector continued to be a stock pickers’ market through 3Q18 as there was a near even split between global biotech stocks that gained and lost value in the quarter. While 1H18 saw investors...
BioCentury | Oct 6, 2018
Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
BC Week In Review | Sep 21, 2018
Clinical News

Progenics' prostate cancer imaging agent meets specificity endpoint in Phase III

Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) said SPECT/CT imaging with its 99mTc-MIP-1404 (1404, F-1311) imaging agent met the co-primary endpoint of specificity but missed the co-primary endpoint of sensitivity in a Phase III trial to detect low-grade...
Items per page:
1 - 10 of 565